fda warning letters compounding semaglutide october 2025 alerts health care providers, compounders and patients of dosing errors associated with compounded injectable products FDA warns consumers not to – A shadowy market for weight-loss

Taking penta deca peptide arginate orally means retaining approximately 95% of the dose through gastric transit

Injections or pills

If you are low in Vitamin B12 or have a deficiency anaemia, you will not be creating enough red blood cells and the ones you do make might be defective, being abnormally large

In June 2025, MBX Biosciences announced that it has submitted an IND application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug targeting obesity, which received regulatory clearance in July

Caution is advised for patients with a history of pancreatitis, gallbladder disease, kidney disease, diabetic retinopathy, or gastrointestinal motility disorders

No previously studied medication achieved average weight loss exceeding 20% at one year